Background Lithium is a first-line treatment in bipolar disorder, but individual response is
variable. Previous studies have suggested that lithium response is a heritable trait. However, …

Background Environmental conditions early in life may imprint the circadian system and
influence response to environmental signals later in life. We previously determined that a large …

Bipolar disorder (BD) is a genetically complex mental illness characterized by severe
oscillations of mood and behaviour. Genome-wide association studies (GWAS) have identified …

Objective The assessment of response to lithium maintenance treatment in bipolar disorder (BD)
is complicated by variable length of treatment, unpredictable clinical course, and often …

For more than half a decade, lithium has been successfully used to treat bipolar disorder.
Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and …

Importance Lithium is a first-line mood stabilizer for the treatment of bipolar affective disorder
(BPAD). However, the efficacy of lithium varies widely, with a nonresponse rate of up to 30%…

Lithium is a first-line medication for bipolar disorder (BD), but only one in three patients
respond optimally to the drug. Since evidence shows a strong clinical and genetic overlap …

Lithium is the gold standard therapy for Bipolar Disorder (BD) but its effectiveness differs
widely between individuals. The molecular mechanisms underlying treatment response …

Aims: Bipolar disorder (BD) is a lifelong psychiatric illness characterized by manic and
depressive episodes affecting 1–5% of the general population. Among mood-stabilizing …

Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling
mental health disorder that affects about 1% of the population worldwide. Nevertheless, …